WP
LXEO icon

Woodline Partners’s Lexeo Therapeutics LXEO Stock Holding History

Woodline Partners’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Sell
2,500,532
-250,000
-9% -$1.35M 0.04% 494
2026
Q1 		$15.8M Sell
2,750,532
-447,228
-14% -$3.17M 0.06% 392
2025
Q4 		$31.8M Buy
3,197,760
+625,598
+24% +$5.71M 0.12% 212
2025
Q3 		$17.1M Hold
2,572,162
– – 0.08% 319
2025
Q2 		$10.3M Buy
2,572,162
+1,735,148
+207% +$5.71M 0.05% 424
2025
Q1 		$2.9M Sell
837,014
-21,677
-3% -$96K 0.02% 610
2024
Q4 		$5.65M Buy
858,691
+6,730
+0.8% +$53K 0.04% 462
2024
Q3 		$7.7M Buy
851,961
+27,887
+3% +$333K 0.06% 336
2024
Q2 		$13.2M Buy
824,074
+812,023
+6,738% +$11.8M 0.13% 219
2024
Q1 		$189K Buy
+12,051
New +$188K ﹤0.01% 517

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Woodline Partners's LXEO Position: Q2 2026 in Review

Woodline Partners reduced its Lexeo Therapeutics (LXEO) stake by 9.1% in Q2 2026, selling an estimated $1.35M and leaving 2,500,532 shares worth $11.6M. The position accounts for 0.04% of the portfolio, ranked #494.

Woodline Partners first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. The position peaked at $31.8M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Woodline Partners held 2,500,532 shares of Lexeo Therapeutics worth $11.6M as of Q2 2026.
  • Woodline Partners sold 250,000 Lexeo Therapeutics shares in Q2 2026, an estimated $1.35M.
  • Lexeo Therapeutics made up 0.04% of Woodline Partners's portfolio in Q2 2026, its #494 holding.
  • Woodline Partners first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Woodline Partners's Lexeo Therapeutics position peaked at $31.8M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.